Program
anlotinib
Also written as “Anlotinib”, “AL3818” and “AK104+anlotinib”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Endometrial Neoplasms · Small Cell Lung Carcinoma · Neoplasms · Sarcoma, led by 8 companies.
Drug pageAnlotinib: every studyMany companies study it; this page follows only the 40 they lead. All 374 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceuticalits history only | 311 open or running | phase 3since Dec 30, 2013 | Mar 29, 2013 | none ahead |
| Advenchen Laboratoriesits history only | 32 open or running | phase 3since Aug 28, 2015 | Sep 26, 2014 | Dec 2027phase 3 · NCT03016819 |
| Advenchen Laboratories Nanjingits history only | 11 open or running | phase 1since Feb 11, 2026 | Feb 11, 2026 | Mar 31, 2027phase 1 · NCT07438886 |
| Advenchen Pharmaceuticals, LLC. | 11 open or running | phase 2since Aug 12, 2026 | Aug 12, 2026 | Sep 1, 2030phase 2 · NCT07811297 |
| Akesoits history only | 10 open or running | phase 2since Nov 23, 2020 | Nov 23, 2020 | none ahead |
| Fosun Pharmaits history only | 11 open or running | phase 2since Apr 25, 2026 | Apr 25, 2026 | Jun 2029phase 2 · NCT07562581 |
| Lyvgen Biopharmaits history only | 10 open or running | phase 2since Mar 2, 2022 | Mar 2, 2022 | none ahead |
| Shanghai Gopherwood Biotechits history only | 11 open or running | phase 2since Jan 12, 2023 | Jan 12, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Advenchen Pharmaceuticals, LLC. only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 12, 2026First study: phase 2 study in Endometrial NeoplasmsFirst studyNCT07811297 · 138 planned · United States
Ahead
- Sep 1, 2030Primary completion: phase 2 study in Endometrial NeoplasmsNCT07811297
TargetBeta
“Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor beta inhibitor”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| regorafenibrule | Bayer | phase 4 | 40 |
Studies
The one study Advenchen Pharmaceuticals, LLC. leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07811297Endometrial Neoplasms · United States | 2 | Not yet recruiting | Sep 1, 2030 | 138 |
How it is read
Names in the registry
- “Anlotinib”, 27 entries
- “AL3818”, 5 entries
- “AK104+anlotinib”, 3 entries
- “luvometinib + anlotinib”, 2 entries
- “Anlotinib and 14C-labeled Anlotinib”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 7 studies
- Endometrial Neoplasms, 4 studies
- Small Cell Lung Carcinoma, 4 studies
- Neoplasms, 3 studies
- Sarcoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.